Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Rich JN, et al. Among authors: reardon da. J Clin Oncol. 2004 Jan 1;22(1):133-42. doi: 10.1200/JCO.2004.08.110. Epub 2003 Nov 24. J Clin Oncol. 2004. PMID: 14638850 Clinical Trial.
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Reardon DA, et al. Neuro Oncol. 2004 Apr;6(2):134-44. doi: 10.1215/s1152851703000413. Neuro Oncol. 2004. PMID: 15134628 Free PMC article. Clinical Trial.
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE 2nd, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Quinn JA, et al. Among authors: reardon da. Neuro Oncol. 2004 Apr;6(2):145-53. doi: 10.1215/S1152851703000498. Neuro Oncol. 2004. PMID: 15134629 Free PMC article. Clinical Trial.
Kluver-Bucy syndrome related to glioma.
Badruddoja MA, Vredenburgh J, Peery TS, Reardon DA. Badruddoja MA, et al. Among authors: reardon da. Neurology. 2004 Jul 13;63(1):184. doi: 10.1212/01.wnl.0000132961.60435.b7. Neurology. 2004. PMID: 15249638 No abstract available.
Monoclonal antibodies for brain tumour treatment.
Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Boskovitz A, et al. Among authors: reardon da. Expert Opin Biol Ther. 2004 Sep;4(9):1453-71. doi: 10.1517/14712598.4.9.1453. Expert Opin Biol Ther. 2004. PMID: 15335313 Review.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN. Goudar RK, et al. Among authors: reardon da. Mol Cancer Ther. 2005 Jan;4(1):101-12. Mol Cancer Ther. 2005. PMID: 15657358
Chemotherapy and novel therapeutic approaches in malignant glioma.
Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Desjardins A, et al. Among authors: reardon da. Front Biosci. 2005 Sep 1;10:2645-68. doi: 10.2741/1727. Front Biosci. 2005. PMID: 15970525 Review.
381 results